Almirall Beheer

Mr. Carlos Gallardo Piqué serves as President at Almirall S. A. since January 2024. He has been Chairman of Board at Almirall, S.A. since May 06, 2022. He serves as Chief Executive Officer at Almirall, S.A...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos Gallardo Piqué	CEO, President	2.8yrs	€50.00k	geen gegevens
Michael McClellan	CFO & Member of Management Board	5yrs	geen gegevens	geen gegevens
Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	no data	geen gegevens	geen gegevens
Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	no data	geen gegevens	geen gegevens
Volker Koscielny	Chief Medical Officer & Member of Management Board	4.8yrs	geen gegevens	geen gegevens
Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	3.8yrs	geen gegevens	geen gegevens
Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	3.8yrs	geen gegevens	geen gegevens
Isabel Gomes	Company Vice Secretary	2.8yrs	geen gegevens	geen gegevens
Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	2.8yrs	geen gegevens	geen gegevens
Paul Rittman	Member of Management Board and President & GM of Almirall US	less than a year	geen gegevens	geen gegevens
Pablo del Fraile	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Xavier Alba	Acting CSO and Head of R&D	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van ALM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos Gallardo Piqué	CEO, President	10.3yrs	€50.00k	geen gegevens
Sidney Taurel	Member of Global Advisory Board-Spain	15.8yrs	geen gegevens	geen gegevens
Enrique de Leyva Perez	Vice-Chair & Lead Independent Director	5.8yrs	geen gegevens	0.0098% € 183.1k
Karin Louise Dorrepaal	External Independent Director	11.8yrs	€122.00k	geen gegevens
Eva-Lotta Coulter	Independent Director	4.2yrs	geen gegevens	geen gegevens
Ruud Dobber	Independent Director	3.4yrs	geen gegevens	geen gegevens
Ugo Francesco	Independent Director	less than a year	geen gegevens	geen gegevens
Antonio Gallardo Torrededia	Proprietary Director	10.3yrs	€50.00k	geen gegevens
Seth Orlow	External Independent Director	8.5yrs	geen gegevens	geen gegevens
Alexandra Kimball	Independent Director	4.2yrs	geen gegevens	geen gegevens
Eva Iglesias	Independent Director	less than a year	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Almirall Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A., Annual General Meeting, May 05, 2023

Almirall, S.A. Announces Executive Changes

Recent updates

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Is Almirall (BME:ALM) Using Too Much Debt?